Replies to post #392100 on Amarin Corp Plc (AMRN)

[couldbebetter]

Their treatment requires an infusion every two weeks and the benefit is
negligible. 20% of those getting treatment experience some form of brain
swelling or bleeding. Of course, with BP backing this expensive, risky,
and barely effective medication is sure to get FDA approval. Unless or
until AMRN is owned by BP nobody will care if Vascepa is effective in
treating Alzheimer's disease of CVD for that matter. Let's hope that
Denner begins his game plan soon.

[ziploc_1]

Biogen is spending hundreds of millions of dollars and possibly over a billion to demonstrate the real fact that there is a correlation between amyloid deposits in the brain and Alzheimer's cognitive defects...While this is undoubtedly true, an equally important question is...what was the impetus for the amyloid deposits to start forming in the brain in the first place...IMHO the answer may be...inflammation in the brain.

This is where EPA may be of help....a BP could supply the necessary funds to do the research to show this.